Esophageal Cancer: Current Advances and Controversies
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Sandra Starnes, MD
Inderpal Sarkaria, MD
Presentations
- Endoscopic Therapy for Early-Stage Esophageal Cancer
Robert Van Haren, MD, MSPH
- Optimal Treatment for Esophageal Adenocarcinoma: CROSS
Monisha Sudarshan, MD MPH
Disclosure(s): Ethicon Johnson & Johnson: Advisory Board (Terminated, June 3, 2024)
- Optimal Treatment for Esophageal Adenocarcinoma: FLOT
Jonathan Cools-Lartigue, MD, PhD
- Panel Discussion
- Surveillance Versus Resection Following Induction Therapy for Esophageal Cancer
Biniam Kidane, MD MSc FRCSC
Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Unrestricted Educational grant (Ongoing); Merck: Advisory Board (Terminated, January 1, 2023), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2023); Olympus: Consultant (Ongoing); Roche: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
- Emerging Biomarkers in Esophageal Cancer (MSI/MMR, HER2, PDL) and Implications For Treatment
Daniela Molena, MD
Disclosure(s): Boehringer: Consultant (Terminated, February 21, 2024)
- Panel Discussion
- Esophagectomy vs. Gastrectomy for Gastroesophageal Junction Tumors
Stephanie G. Worrell, MD
Disclosure(s): Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
- Open Esophagectomy: Tips and Techniques
Richard J. Battafarano, MD PhD
- RAMIE Tips and Tricks: Is RAMIE the Preferred Approach? Update on Trials
Lana Schumacher, MD, MS, FACS
Disclosure(s): Medtronic: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); DaVinci Intuitive Surgical: Consultant (Ongoing)
- Panel Discussion
- Post-Esophagectomy Diet Management: Early Esophagram and Diet Advancement
Luis F. Tapias, MD
Disclosure(s): AstraZeneca: Advisory Board (Terminated, January 31, 2024); Intuitive Surgical: Consultant (Terminated, December 31, 2023)
- Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Three-Year National Perspective
Sara Sakowitz, MS, MPH
Available Credit
- 2.00 ABS Accredited CME
- 2.00 ABTS Accredited CME
- 2.00 AMA PRA Category 1 Credit™
Price
Cost:
$0.00
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Sandra Starnes, MD
Inderpal Sarkaria, MD
Presentations
- Endoscopic Therapy for Early-Stage Esophageal Cancer
Robert Van Haren, MD, MSPH
- Optimal Treatment for Esophageal Adenocarcinoma: CROSS
Monisha Sudarshan, MD MPH
Disclosure(s): Ethicon Johnson & Johnson: Advisory Board (Terminated, June 3, 2024)
- Optimal Treatment for Esophageal Adenocarcinoma: FLOT
Jonathan Cools-Lartigue, MD, PhD
- Panel Discussion
- Surveillance Versus Resection Following Induction Therapy for Esophageal Cancer
Biniam Kidane, MD MSc FRCSC
Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Unrestricted Educational grant (Ongoing); Merck: Advisory Board (Terminated, January 1, 2023), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2023); Olympus: Consultant (Ongoing); Roche: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
- Emerging Biomarkers in Esophageal Cancer (MSI/MMR, HER2, PDL) and Implications For Treatment
Daniela Molena, MD
Disclosure(s): Boehringer: Consultant (Terminated, February 21, 2024)
- Panel Discussion
- Esophagectomy vs. Gastrectomy for Gastroesophageal Junction Tumors
Stephanie G. Worrell, MD
Disclosure(s): Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
- Open Esophagectomy: Tips and Techniques
Richard J. Battafarano, MD PhD
- RAMIE Tips and Tricks: Is RAMIE the Preferred Approach? Update on Trials
Lana Schumacher, MD, MS, FACS
Disclosure(s): Medtronic: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); DaVinci Intuitive Surgical: Consultant (Ongoing)
- Panel Discussion
- Post-Esophagectomy Diet Management: Early Esophagram and Diet Advancement
Luis F. Tapias, MD
Disclosure(s): AstraZeneca: Advisory Board (Terminated, January 31, 2024); Intuitive Surgical: Consultant (Terminated, December 31, 2023)
- Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Three-Year National Perspective
Sara Sakowitz, MS, MPH